tiprankstipranks
In this article:
Blurbs

JMP Securities Keeps a Buy Rating on CTI BioPharma (CTIC)

In this article:
In this article:

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on CTI BioPharma (CTICResearch Report), with a price target of $4.00. The company’s shares closed last Tuesday at $2.10.

According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.6% and a 34.0% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

CTI BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $5.55, representing a 180.3% upside. In a report issued on December 1, Needham also reiterated a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $4.13 and a one-year low of $1.43. Currently, CTI BioPharma has an average volume of 1.68M.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CTIC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed